Has Julie Prieboy received payments from drug or device companies?

Yes. Drug and device makers reported $10,930 in general payments to Julie Prieboy across 442 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Julie Prieboy did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Julie Prieboy come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Julie Prieboy

Oncology · Munster, INNPI 1366743114

Payments from drug & device makers

$10,930in general payments, 2019–2025

Across 442 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2K
AstraZeneca$1K
Johnson & Johnson$851
E.r. Squibb & Sons, L.L.C.$557
Pfizer$469
AbbVie$413
plus $6K from 54 others

What the payments were for

Food & beverage$9,20184%
Education$4504%
Other$1,28012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	33	$1,736
AstraZeneca(2 entities)	48	$1,111
Johnson & Johnson(2 entities)	32	$851
E.r. Squibb & Sons, L.L.C.	27	$557
Pfizer	27	$469
AbbVie	18	$413
Daiichi Sankyo Inc.	16	$379
Amgen	12	$370
Astellas Pharma US Inc	10	$364
Bristol Myers Squibb	17	$340
Merck	16	$291
Takeda Pharmaceuticals U.S.A., Inc.	9	$249
Incyte Corporation	13	$242
Gilead(2 entities)	11	$229
Genentech USA, Inc.	7	$174
Jazz Pharmaceuticals Inc.	6	$163
Deciphera Pharmaceuticals Inc.	7	$158
Sanofi	7	$146
Pharmacyclics LLC, An Abbvie Company	6	$133
Eisai Inc.	7	$123
Array Biopharma Inc	7	$121
ADC Therapeutics America, Inc.	6	$117
Sumitomo Pharma America, Inc.	4	$112
GSK	5	$111
Bayer	6	$110
Seagen Inc.	5	$107
Acrotech Biopharma Inc.	4	$106
Stemline Therapeutics Inc.	4	$98
Ipsen Biopharmaceuticals, Inc	3	$92
Regeneron Healthcare Solutions, Inc.	4	$76
Tersera Therapeutics LLC	3	$76
Agios Pharmaceuticals, Inc.	4	$73
Morphosys, US Inc.	4	$73
Adaptive Biotechnologies Corporation	3	$70
Caris MPI, Inc.	2	$68
Beigene USA, Inc.	3	$66
Exelixis Inc.	3	$62
Servier Pharmaceuticals LLC	3	$57
Mirati Therapeutics, Inc.	2	$48
Iovance Biotherapeutics, Inc.	2	$47
Rigel Pharmaceuticals, Inc.	2	$45
AVEO Pharmaceuticals, Inc.	2	$42
Tolmar Pharmaceuticals, Inc.	2	$39
Pharmaessentia USA Corporation	2	$39
Pharming Healthcare, Inc.	2	$39
Myovant Sciences Inc.	2	$36
Alnylam Pharmaceuticals Inc.	2	$35
Acceleron Pharma, Inc.	2	$34
Syndax Pharmaceuticals, Inc.	1	$34
Puma Biotechnology, Inc.	2	$32
Karyopharm Therapeutics Inc.	2	$32
Springworks Therapeutics, Inc.	1	$31
Coherus Oncology, Inc.	1	$31
Tactile Systems Technology Inc	1	$27
Stryker	1	$26
Beone Medicines USA, Inc.	1	$25
Sobi, Inc	1	$25
Clovis Oncology, Inc.	1	$23
Boehringer Ingelheim	1	$23
Azurity Pharmaceuticals, Inc.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TAGRISSO$129

How this compares

Too few oncology providers in Indianato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CabometyxCabozantinib S-Malate	13	$359,698
KisqaliRibociclib Succinate	27	$328,550
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	236	$6,657
Ondansetron Hcl	37	$4,630
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	26	$1,244
Megestrol Acetate	16	$1,135
Pregabalin	24	$842
Morphine Sulfate ErMorphine Sulfate	28	$830
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine	28	$807
Gabapentin	56	$640
Lactulose	23	$478
Anastrozole	45	$468
Duloxetine Hcl	18	$436
ConstuloseLactulose	11	$292
Prednisone	59	$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Exelixis Inc.Cabometyx	$62	$359,69813 claims
NovartisKisqali	$1,736	$328,55027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few oncology providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other oncology in Munster

Patricia AvilaMuncie$84
Sarah CookFort Wayne$18

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →